Skip to main content
. 2021 Oct 22;12(4):2103–2119. doi: 10.1016/j.apsb.2021.10.010

Figure 5.

Figure 5

In vivo homologous-targeting fluorescence imaging and antitumor treatment on mice. (A) In vivo images of mice after tail vein injection of BMS/RA@Liposome, BMS/RA@RBC-Liposome and BMS/RA@CC-Liposome at 1, 4, 8, 12, and 24 h, respectively. (B) Ex vivo images of tumor and other tissues from the mice after 24 h administration with the different formulations. 1: heart; 2: liver; 3: spleen; 4: lung; 5: kidney; 6: tumor. (C) Quantification of fluorescence intensity of (A) (n = 3). (D) Quantification of fluorescence intensity of (B) (n = 3). (E) Changes of tumor volume upon different treatments (n = 8). (F) Changes of body weight upon different treatments (n = 8). (G) Tumors weight of mice with different formulations treatment at the end point of the experiment (n = 8). (H) Representative images of the CT26 tumors after treatment with different formulations on Day 22. I: Control group; II: BMS@CC-Liposome group; III: RA-V@CC-Liposome group; IV: BMS/RA@CC-Liposome group. (I) Representative H&E stained images of tumor slices collected from different groups of mice upon different treatments. Scale bar = 50 μm. Data are given as mean ± SD. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.